Form 4 for ANGO ANGIODYNAMICS INC
Accepted 2022-07-22 00:00:00 ET · period of report 2022-07-20 · accession 0001567619-22-014371 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-07-22 | 2022-07-20 | ANGO | Piccinini Laura | SVP International | A - Grant | $0.00 | +4,402 | 7,354 | +149% | $0 |
| DM | 2022-07-22 | 2022-07-20 | ANGO | Piccinini Laura | SVP International | A - Grant | $0.00 | +19.1K | 10.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-20 | A | A | 4,402 | $0.00 | 7,354 | D | — | — | (F1) The acquisition of 4,402 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 4,402 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 20, 2023, such that 25% of the restricted stock units will vest on each of July 20, 2023, 2024, 2025 and 2026. |
| 2 | Derivative | Performance Right | 2022-07-20 | A | A | 8,803 | $0.00 | 8,803 | D | — · — to — | 8,803 Common Stock | (F2) Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. |
| 3 | Derivative | Non- Qualified Stock Option (right to buy) | 2022-07-20 | A | A | 10,312 | $0.00 | 10,312 | D | $21.53 · 2023-07-20 to 2032-07-20 | 10,312 Common Stock | (F3) These stock options vest in four equal annual installments beginning on July 20, 2023, such that 25% of the options will vest on each of July 20, 2023, 2024, 2025 and 2026. |